Literature DB >> 20693982

ERG rearrangement is present in a subset of transition zone prostatic tumors.

Sara M Falzarano1, Maria Navas, Kelly Simmerman, Eric A Klein, Mark A Rubin, Ming Zhou, Cristina Magi-Galluzzi.   

Abstract

A majority of prostate cancers exhibit a recurrent gene rearrangement involving chromosome 21. In approximately 90% of cases, the rearrangement is characterized by fusion of the androgen-regulated gene TMPRSS2 with the oncogene ERG. A recent study suggested that TMPRSS2-ERG gene fusion is lacking in cancers arising from the transition zone of the prostate. A dominant transition zone cancer was detected in 62/397 (16%) patients who underwent radical prostatectomy at our institution and were reviewed and mapped by a single pathologist. In 46/62 specimens, a secondary tumor was identified in the peripheral zone of the prostate. A tissue microarray containing both transition and peripheral zone tumors was constructed and evaluated for gene fusion analysis. TMPRSS2-ERG fusion status was determined using a multicolor interphase fluorescence in situ hybridization assay for ERG break-apart. The median age of the patients was 59 years. Prostatectomy Gleason score was 6 in 21, 7 in 34, and ≥8 in 7 cases. Median tumor volume was 200 mm(2). TMPRSS2-ERG gene fusion was present in 7/59 (12%) transition zone, and in 12/35 (34%) peripheral zone tumors. Transition zone fusion-positive cases were larger than their negative counterparts. No significant correlation was found between fusion status and Gleason score or pathologic stage. Gene fusion through deletion occurred in 4/7 transition zone and 7/12 peripheral zone tumors. Transition zone prostate cancers are considered biologically and genetically different from peripheral zone tumors. Although ERG rearrangement is more common in peripheral zone tumors, we have detected TMPRSS2-ERG fusion in a subset of transition zone cancers (12%). The lower frequency of gene fusion in transition zone prostate cancer may suggest distinct molecular alterations from peripheral zone tumors and the association with a high tumor volume may indicate a growth advantage for transition zone tumors harboring the gene fusion. Further studies are necessary to confirm this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20693982     DOI: 10.1038/modpathol.2010.150

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  17 in total

1.  Molecular differences in transition zone and peripheral zone prostate tumors.

Authors:  Jennifer A Sinnott; Jennifer R Rider; Jessica Carlsson; Travis Gerke; Svitlana Tyekucheva; Kathryn L Penney; Howard D Sesso; Massimo Loda; Katja Fall; Meir J Stampfer; Lorelei A Mucci; Yudi Pawitan; Sven-Olof Andersson; Ove Andrén
Journal:  Carcinogenesis       Date:  2015-04-13       Impact factor: 4.944

2.  ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.

Authors:  Sean R Williamson; Shaobo Zhang; Jorge L Yao; Jiaoti Huang; Antonio Lopez-Beltran; Steven Shen; Adeboye O Osunkoya; Gregory T MacLennan; Rodolfo Montironi; Liang Cheng
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

3.  TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimens.

Authors:  Ömer Yılmaz; Ufuk Berber; Sezgin Okçelik; Hasan Soydan; Ferhat Ateş; Kenan Karademir
Journal:  Turk J Urol       Date:  2016-06

4.  The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.

Authors:  Andreas Pettersson; Rebecca E Graff; Scott R Bauer; Michael J Pitt; Rosina T Lis; Edward C Stack; Neil E Martin; Lauren Kunz; Kathryn L Penney; Azra H Ligon; Catherine Suppan; Richard Flavin; Howard D Sesso; Jennifer R Rider; Christopher Sweeney; Meir J Stampfer; Michelangelo Fiorentino; Philip W Kantoff; Martin G Sanda; Edward L Giovannucci; Eric L Ding; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-26       Impact factor: 4.254

5.  Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas.

Authors:  Antoun Toubaji; Roula Albadine; Alan K Meeker; William B Isaacs; Tamara Lotan; Michael C Haffner; Alcides Chaux; Jonathan I Epstein; Misop Han; Patrick C Walsh; Alan W Partin; Angelo M De Marzo; Elizabeth A Platz; George J Netto
Journal:  Mod Pathol       Date:  2011-07-08       Impact factor: 7.842

Review 6.  ERG expression in prostate cancer: biological relevance and clinical implication.

Authors:  Hatem Abou-Ouf; Liena Zhao; Tarek A Bismar
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-28       Impact factor: 4.553

Review 7.  Emerging critical role of molecular testing in diagnostic genitourinary pathology.

Authors:  George J Netto; Liang Cheng
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

8.  ERG gene rearrangement status in prostate cancer detected by immunohistochemistry.

Authors:  Sara Moscovita Falzarano; Ming Zhou; Paula Carver; Toyonori Tsuzuki; Kelly Simmerman; Huiying He; Cristina Magi-Galluzzi
Journal:  Virchows Arch       Date:  2011-07-20       Impact factor: 4.064

9.  TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.

Authors:  Anuradha Gopalan; Margaret A Leversha; Maria E Dudas; Alexandra C Maschino; Jeremy Chang; Hikmat A Al-Ahmadie; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter; Samson W Fine
Journal:  Histopathology       Date:  2013-05-23       Impact factor: 5.087

10.  ERG expression and prostatic adenocarcinoma.

Authors:  Montse Verdu; Isabel Trias; Ruth Roman; Natalia Rodon; Beatriz Garcia-Pelaez; Miquel Calvo; Arturo Dominguez; Josep M Banus; Xavier Puig
Journal:  Virchows Arch       Date:  2013-05-24       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.